🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

❗️Further results for Semaglutide ❗️ ESSENCE trial - preliminary data only 🔹Sema 2.4mg OW vs placebo in MASH and stage 2-3 liver fibrosis 🔸Liver histology assessed for 800 pts at 72 weeks 🔹Primary endpoint achieved 🔸Resolution of steatohepatitis with no worsening of

In > 18,000 Chinese #T2D individuals from Hong Kong, we utilized the latest pathway-specific polygenic risk scores (psPRS) to dissect the heterogeneity in disease progression and diabetic complications (P1). rdcu.be/d0hw3 Dr Ronald Ma Richard Oram @mnweedon CUHK Medicine

Great talks at #ATTDASIA24 on potential of tirzepatide in #T1d, David Pamzirer on whole-person care, menin inhibition with icovamenib, #AHCL in Asians and more. Thanks to Tadej Battelino and team! Lovely connecting with so many ppl and looking forward next year! Advanced Technologies & Treatments for Diabetes

Great to have our young #CUHK team represented at the first #ATTDASIA24! Well done with all the presentations! Dr Ronald Ma CUHK Medicine @julianachan_HK YouthDiabetesAction

Results From a Randomized Trial of Intensive Glucose Management Using CGM Versus Usual Care in Hospitalized Adults With Type 2 Diabetes: The TIGHT Study Diabetes Care, a research journal of the ADA 🌟 🖇️ diabetesjournals.org/care/article/d…

#ClinicalTrials are followed by decades of suboptimal #implementation. Are we too focussed on regulatory approval and not enough on implementation when designing #phase3 #RCTs? Our guide to designing RCTs for implementation w illustrative examples 1/ authors.elsevier.com/a/1k2Nc2d9GH%7…

Study shows that the relationship between insulin demand & insulin adequacy changes throughout the life course. RAD, a novel index, efficiently describes this relationship & evaluates risk of glycaemic intolerance Yingchai Zhang CUHK Medicine Dr Ronald Ma tinyurl.com/yc26t39v 🔓

Kindly invited to read 👇🏼👇🏼 The Virtual DCCT: Adding Continuous Glucose Monitoring to a Landmark Clinical Trial for Prediction of Microvascular Complications | DTT liebertpub.com/doi/10.1089/di… Emma Wilmot Pratik Choudhary Prof Kamlesh Khunti Partha S Kar 🇮🇳🇬🇧🏏🎥 Advanced Technologies & Treatments for Diabetes IDFEurope / Diabetes #dedoc°

Definition and diagnostic criteria of clinical obesity - The Lancet Diabetes & Endocrinology thelancet.com/journals/landi… here The Obesity Society Endocrine Society AACE

Statins ⤵️ CVD risk & cost-effectively improve QALYs in older adults❗️ 🔹 UK study: Statins ⤵️ CVD events by ~24% & CV deaths by ~12%. 🔸Cost-effective for those ≥70 years, regardless of LDL levels or prior CVD. ❗️Emphasizes the importance of statins in preventive care for

Please do share the first of several publications from our findings of the Diabetes UK funded #UNBIASED national study, which addresses a pressing issue of health inequalities in access to diabetes technologies for individuals living with #Type1 #diabetes in the UK. Key

Relationship of haptoglobin phenotype and levels with sight-threatening diabetic retinopathy in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in diabetes (FIELD) substudy - Diabetes Research and Clinical Practice diabetesresearchclinicalpractice.com/article/S0168-…

#CGM improves detection of glycemic excursions in hemodialysis patients with #T2D CGM improved the detection of hyper & hypo, p nocturnal and prolonged hypos academic.oup.com/jcem/article-a…

Congratulations Prof @julianachan_HK CUHK Medicine on the 2025 Kelly West Award from American Diabetes Association - DiabetesPro! Thank you for your tireless effort for people living with diabetes!

Miss #ATTD2025 already? Don’t worry—#IHSGAdvances2025 is just around the corner! Join us on April 30 for a dynamic, one-day virtual conference focused on all things hypoglycemia. 🧠 Learn. 📣 Share. 💥 Advance the field. 📅 REGISTER NOW!!

Subcutaneous semaglutide demonstrated cardiovascular benefit in T2DM back in 2016 (SUSTAIN-6) with 26% MACE reduction. Oral semaglutide demonstrates cardiovascular risk reduction in T2DM and high CV risk in the newly published SOUL trial with 14% MACE reduction with albeit a

IDF 2025 has come to a close! A heartfelt thank you to the more than 6,800 participants from over 165 countries and territories who joined us to shape the future of diabetes care and advocacy! We look forward to welcoming you in 2027 for next our World Diabetes Congress, in Doha,

Congrats to Prof J Chan for the #ADA2025 Kelly West award in epidemiology! She is a true inspiration and remains tireless in advancing diabetes care. My honor to be working with her. CUHK Medicine

Honored to speak at the #ATTDonUNLOK Webinar on 1 July, 12:00 CEST! Will be speaking about use of #AI and #CGM for dietary and lifestyle interventions in #prediabetes. Practical sharing with real life cases. Register FREE now: invt.io/1txbx7fv7bg #UNLOKEducation